There have been rapid advancements in the field of ocular oncology for the diagnosis and management of intraocular, adnexal, and orbital tumors. Targeted therapy is in the forefront of medical research in all fields including ocular oncology. Targeted therapy include drugs that target specific genetic mutations, pathways or proteins involved in the development of cancer. In contrast to traditionally used chemotherapy, drugs used in targeted therapy are highly specific for tumor cells and preserve the function of normal cells. This review aims to familiarize ophthalmologists with the drugs that are currently approved or undergoing clinical trials for use in ocular oncology. Targeted therapy is particularly useful for locally advanced or metastatic tumors, including but not limited to eyelid and periocular basal cell carcinoma, periocular cutaneous and conjunctival squamous cell carcinoma, ocular adnexal lymphoma, conjunctival melanoma, and uveal melanoma. The results are promising with improved survival outcomes and better tolerability than chemotherapeutic drugs.
Keyphrases
- squamous cell carcinoma
- palliative care
- basal cell carcinoma
- clinical trial
- current status
- optic nerve
- small cell lung cancer
- induced apoptosis
- healthcare
- magnetic resonance
- locally advanced
- randomized controlled trial
- open label
- papillary thyroid
- drug induced
- radiation therapy
- cell proliferation
- magnetic resonance imaging
- sensitive detection